Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

Lilly anticipates revenue growth contributions in 2025 from new Lilly medicines such as Jaypirca ... Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on LLY: Eli Lilly NewsMORE Related ...

While the U.S. incretin market grew 45% compared to the same quarter last year, our previous guidance had anticipated even faster acceleration ...

TWENTY-six projects from eleven Limerick schools that have qualified for the BT Young Scientist & Technology Exhibition ...

MSD has expanded its presence in Ireland with an agreement to buy a vaccine manufacturing facility from Chinese biotech WuXi ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other healthcare stocks Jim Cramer has made bold predictions about. Healthcare has been ...

Eli Lilly's new FDA clearance could provide it an advantage, but Novo Nordisk's calculated changes show its will to remain a major participant. As celebrities like Musk draw attention to these ...

Danny O’Donoghue, 42, of Lower Main Street, Rathkeale, appeared before a special late sitting of Limerick District Court on Christmas Eve, charged with dangerous driving causing Ms O’Rourke ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop ...